Longshenrongfa Pharmaceutical Industry released its first-quarter performance, with a net profit attributable to the parent company of 24.21 million yuan, an increase of 9.18%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Longshenrongfa Pharmaceutical Industry released its first-quarter report for 2025, with operating revenue of 289 million yuan, a year-on-year increase of 13.52%. The net profit attributable to shareholders of the listed company was 24.21 million yuan, a year-on-year increase of 9.18%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 26.923 million yuan, a year-on-year increase of 26.88%. The basic earnings per share were 0.0798 yuan
According to the Zhitong Finance APP, Longshenrongfa Pharmaceutical Industry (300534.SZ) released its first-quarter report for 2025, reporting an operating income of 289 million yuan, a year-on-year increase of 13.52%. The net profit attributable to shareholders of the listed company was 24.21 million yuan, a year-on-year increase of 9.18%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 26.923 million yuan, a year-on-year increase of 26.88%. The basic earnings per share were 0.0798 yuan